Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Recruiting

Phase 2

Decitabine/CedazuridineDecitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05960773

Conditions

Mesothelioma

Malignant Mesothelioma (MM)

Early-stage Mesothelioma

Subclinical Mesothelioma

BRCA1-Associated Protein-1 (BAP1) Mutations

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Decitabine/cedazuridine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-22. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-02.